Last 31.00 GBp
Change Today +0.125 / 0.40%
Volume 18.9K
SPH On Other Exchanges
As of 11:35 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

sinclair is pharma plc (SPH) Snapshot

31.00 GBp
Previous Close
30.88 GBp
Day High
31.00 GBp
Day Low
31.00 GBp
52 Week High
01/13/14 - 34.00 GBp
52 Week Low
07/10/13 - 23.50 GBp
Market Cap
Average Volume 10 Days
-0.03 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for SINCLAIR IS PHARMA PLC (SPH)

Related News

No related news articles were found.

sinclair is pharma plc (SPH) Related Businessweek News

No Related Businessweek News Found

sinclair is pharma plc (SPH) Details

Sinclair IS Pharma plc, a specialty pharmaceutical company, provides surface technology and delivery systems for aesthetics, wound care, and skin care treatments worldwide. The company’s aesthetic dermatology solutions include Kelo-cote, a topical silicone gel used for the management and prevention of hypertrophic and keloid scars; Kelo-Stretch, which helps in rebuilding damaged collagen and regaining skin elasticity; Sculptra, a volumizer designed to stimulate natural collagen growth; Perfectha for the treatment of wrinkles and facial contours; and Succeev hyaluronic acid fillers to treat various indications, such as wrinkles-filling, facial creases depressions reduction, and scar treatment. Its wound care products comprise Flammazine and Flammacerium that are used in the prevention and treatment of severe burns and wounds; and Aloclair Plus for relieving the pain caused by aphthous mouth ulcers and other minor oral lesions. The company’s skin care products include Atopiclair, a non-steroidal topical treatment for the symptomatic relief of atopic, contact allergic, and irritant dermatitis; Papulex, a dermocosmetic product used for cleansing, hydrating, and protecting acne prone skin; Sebclair for the management of skin and scalp seborrhoeic dermatitis; and Bio-Taches products for preventing and reducing pigmentation disorders, such as chloasma, melasma, or dyschromia. Further, it offers other products consisting of Variquel/Haemopressin for the treatment of bleeding oesophageal varices; Aloxi, a 2nd generation 5HT3 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting associated with highly emetogenic chemotherapy and moderately emetogenic chemotherapy; and Decapinol for plaque management. Sinclair IS Pharma plc offers its solutions to hospitals, plastic surgeons, dermatologists, and pharmacists. The company was founded in 1971 and is headquartered in London, the United Kingdom.

144 Employees
Last Reported Date: 10/15/13
Founded in 1971

sinclair is pharma plc (SPH) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 815.0K GBP
Chief Operating Officer and Director
Total Annual Compensation: 559.0K GBP
Compensation as of Fiscal Year 2013.

sinclair is pharma plc (SPH) Key Developments

Sinclair IS Pharma plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended December 31, 2013

Sinclair IS Pharma plc reported unaudited consolidated earnings results for the six months ended December 31, 2013. For the period, the company reported revenue of £24,461,000 compared to £22,950,000 for the same period a year ago. Operating loss was £2,322,000 compared to £5,057,000 last year. Loss before taxation was £2,499,000 compared to £5,776,000 last year. Loss for the period from continuing operations was £2,356,000 or 0.5 pence per basic and diluted share compared to £5,183,000 or 1.2 pence per basic and diluted last year. Loss for the period was £3,400,000 or 0.8 pence per basic and diluted share compared to £5,183,000 or 1.2 pence per basic and diluted last year. Net cash generated from operating activities was £3,359,000 compared to £1,376,000 last year. Purchases of property, plant and equipment was £10,000 compared to £33,000 last year. Purchase of intangible assets was £176,000 against £7,642,000 a year ago. Adjusted EBITDA increased to £1,100,000 compared to £1,000,000 last year. Net debt stood at £9,100,000 at December 31, 2013, increased from £6,900,000 at June 30, 2013 as a result of the cash outflows in the period.

Sinclair IS Pharma plc to Report First Half, 2014 Results on Mar 25, 2014

Sinclair IS Pharma plc announced that they will report first half, 2014 results on Mar 25, 2014

Sinclair IS Pharma plc Announces Sales Results for the Six Months Ended December 31, 2013; Provides Earnings Guidance for the Year Ending June 30, 2014

Sinclair IS Pharma plc announced sales results for the six months ended December 31, 2013. For the period, revenues were £24.5 million compared to £23.0 million for the same period last year. This result was impacted by a number of short-term supply, regulatory and political factors which resulted in approximately £1.6 million of international orders being delayed from first half into second half. Like-for like revenues reduced by 7%. The company also provided earnings guidance for the fiscal 2014. As in previous years it expects a significant second half weighting to revenues which will increase this year by the delayed deliveries from first half and therefore it expect full year LFL revenue growth of around 7%. This implies double-digit LFL growth during second half reflecting a robust sell-out growth rate both in Europe and Internationally. Results for the year ending June 30, 2014 are anticipated to be in-line with market expectations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPH:LN 31.00 GBp +0.125

SPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPH.
View Industry Companies

Industry Analysis


Industry Average

Valuation SPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SINCLAIR IS PHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at